Literature DB >> 26393854

Long-term Follow-up of a Randomized Trial of Radiation With or Without Androgen Deprivation Therapy for Localized Prostate Cancer.

Anthony V D'Amico1, Ming-Hui Chen2, Andrew Renshaw3, Marian Loffredo1, Philip W Kantoff4.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26393854     DOI： 10.1001/jama.2015.8577

Source DB:  PubMed          Journal:  JAMA        ISSN： 0098-7484            Impact factor:   56.272


× No keyword cloud information.
  29 in total

1.  Prostate cancer: Cardiac mortality associated with ADT plus radiotherapy.

Authors:  Michel Bolla; Gilles Créhange
Journal:  Nat Rev Urol       Date:  2015-12-15       Impact factor: 14.432

Review 2.  Systemic Treatment of Prostate Cancer in Elderly Patients: Current Role and Safety Considerations of Androgen-Targeting Strategies.

Authors:  Myrto Boukovala; Nicholas Spetsieris; Eleni Efstathiou
Journal:  Drugs Aging       Date:  2019-08       Impact factor: 3.923

3.  Duration of the anti-androgen in men undergoing 6 months of an LHRH agonist and radiation therapy for unfavorable-risk prostate cancer and the risk of death.

Authors:  N N Sanford; M-H Chen; M Loffredo; A Renshaw; P W Kantoff; A V D'Amico
Journal:  Prostate Cancer Prostatic Dis       Date:  2016-11-08       Impact factor: 5.554

4.  Prostate-Specific Antigen Failure and Risk of Death Within Comorbidity Subgroups Among Men With Unfavorable-Risk Prostate Cancer Treated in a Randomized Trial.

Authors:  Nicholas J Giacalone; Jing Wu; Ming-Hui Chen; Andrew Renshaw; Marian Loffredo; Philip W Kantoff; Anthony V D'Amico
Journal:  J Clin Oncol       Date:  2016-11-01       Impact factor: 44.544

Review 5.  The use of Hormonal Therapy to Augment Radiation Therapy in Prostate Cancer: An Update.

Authors:  Greg Kauffmann; Stanley L Liauw
Journal:  Curr Urol Rep       Date:  2017-07       Impact factor: 3.092

6.  The impact of comorbidity and PSA doubling time on the risk of death in men experiencing PSA failure following radiation therapy with or with androgen deprivation therapy for unfavorable-risk prostate cancer.

Authors:  S A Patel; M-H Chen; M Loffredo; A Renshaw; P W Kantoff; A V D'Amico
Journal:  Prostate Cancer Prostatic Dis       Date:  2017-01-24       Impact factor: 5.554

Review 7.  Cardiovascular Effects of Androgen Deprivation Therapy in Prostate Cancer: Contemporary Meta-Analyses.

Authors:  Jiun-Ruey Hu; Meredith S Duncan; Alicia K Morgans; Jonathan D Brown; Wouter C Meijers; Matthew S Freiberg; Joe-Elie Salem; Joshua A Beckman; Javid J Moslehi
Journal:  Arterioscler Thromb Vasc Biol       Date:  2020-01-23       Impact factor: 8.311

8.  Thapsigargin induces apoptosis of prostate cancer through cofilin-1 and paxillin.

Authors:  Fengyu Huang; Peitao Wang; Xinsheng Wang
Journal:  Oncol Lett       Date:  2018-05-30       Impact factor: 2.967

9.  Impact of time to testosterone rebound and comorbidity on the risk of cause-specific mortality in men with unfavorable-risk prostate cancer.

Authors:  Susan G R McDuff; Ming-Hui Chen; Andrew A Renshaw; Marian J Loffredo; Philip W Kantoff; Anthony V D'Amico
Journal:  Cancer       Date:  2018-01-16       Impact factor: 6.860

Review 10.  Current advances in intratumoral androgen metabolism in castration-resistant prostate cancer.

Authors:  Trevor M Penning; Daniel Tamae
Journal:  Curr Opin Endocrinol Diabetes Obes       Date:  2016-06       Impact factor: 3.243
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.